INTRODUCTION
Chronic discogenic back pain caused by degenerative disc disease is a common ailment affecting the general population. Surgical intervention is recommended when conservative treatment fails to improve the patient's pain. Discectomy and/or spinal fusion have been the standard treatment options and are known to be effective in relieving back pain in the short term. However, the long-term results of these treatment modalities have been reported to be less favorable. 1, 2 Discectomy, by removal of nucleus pulposus, changes the mechanics of the disc and makes the long-term surgical outcome questionable. [3] [4] [5] Fusion surgery also presents its own set of problems such as hardware failure, nonunion, and acceleration of degeneration at the levels adjacent to the fused segments. 1, 6, 7 To avoid this and to treat patients with more physiologic methods, there have been many efforts to replace the disc with various kinds of devices. Currently, there are two categories of disc replacement: total disc replacement (such as SB Charité) and nucleus replacement. In contrast to total disc replacement, nucleus replacement preserves the existing structures, which include the annulus, endplates, and ligaments. Several designs of nucleus replacement products are currently under development, are undergoing clinical trials, or are being sold commercially. 8 The PDN prosthetic disc nucleus (Raymedica, Minneapolis, MN, USA) is a nucleus replacement device that is currently available in many areas of the world including Europe, Latin America, and Asia.
There are a few reports of worldwide clinical results for the PDN device, 9, 10 but to our knowledge, there is no large clinical series that has been reported by only one institute (except feasibility studies in very small patient popula-tions). The purpose of this study is to report the authors' early clinical results for the PDN device and thereby to evaluate the efficacy of the implant in patients with chronic back pain caused by degenerative disc disease.
MATERIALS AND METHODS

Patient Selection
From January 2001 to May 2002, a total of 48 patients underwent partial disc replacement with the PDN device in a spine clinic in Seoul, Korea. The inclusion criterion was chronic discogenic back pain that was not relieved by at least 6 months of conservative care regardless of disc herniation. In patients with a disc herniation and concomitant sciatica, a history of chronic disabling back pain that had lasted at least 6 months must have been present. All patients showed degeneration of the affected disc level on magnetic resonance imaging (MRI). If patients showed degeneration at multiple levels, a discogram was performed to identify the level responsible for the pain. If concordant pain was provoked, the discogram was considered positive and the appropriate disc was treated with the PDN device. If the concordant pain was not provoked or provoked in several levels, the patient was excluded from nucleus replacement and underwent other treatment modalities. Exclusion criteria were previous disc surgery, spondylolisthesis, spinal stenosis, Schmorl nodule, moderate to severe osteoporosis, and disc height of <5 mm.
Data Method
Before surgery, all patients responded to a questionnaire containing a 10-point Visual Analogue Pain Scale (VAS), Oswestry Disability Index, and a Prolo Functional Disability Scale. The VAS questionnaire was subdivided into a leg pain score and a back pain score in patients with disc herniation and sciatica, but only back pain scores were included in this analysis. The questionnaire was repeated when the patients visited the outpatient clinic at 6-week, 3-month, 6-month, and 1-year postoperative visits. An independent reviewer evaluated the clinical outcomes according to MacNab's criteria. 11 The data sets were collected and analyzed.
Plain x-rays and computed tomography (CT) scans were taken immediately after ambulation, and x-rays including dynamic lateral views were taken at every visit. MRI was performed whenever possible after 3 months of surgery. An independent reviewer examined the x-ray and MRI films. Disc heights were measured on lateral plain x-rays, and subsidence and/or sclerotic changes at the endplates were evaluated. Any visible changes on the vertebral endplates and vertebral bodies on the MRI scans were recorded.
Operative Technique
Three different surgical approaches were used to implant PDN devices. The first technique is a posterior approach, similar to a conventional discectomy. The patient is placed in a prone position, and a paramedian skin incision is made in the longitudinal direction. Fascia and muscle tissues are incised and retracted. The laminotomy and flavectomy are done in the usual way. A small, transverse annulotomy is made instead of creating a large opening in the annulus. An extensive discectomy is performed, and an effort is made to remove all the nucleus material, so as to create enough room for the PDN device. After discectomy, serial annular dilators are used to dilate the annulotomy, and device sizers are inserted to confirm the proper PDN device size that should be implanted. Properly sized anterior and posterior PDN devices are then selected and connected with a suture before being inserted into the disc space. The anterior device is introduced into the space and rotated in a transverse direction, using a specially designed flexible guide that is inserted beforehand. The posterior device is introduced in the same way, and the two devices are knotted together with suture.
The second approach is the paraspinal transforaminal approach, which was developed by one of the authors. The patient is placed in the prone position, and the skin incision is made 5-6 cm lateral to the midline. Fascia and muscle dissection is done in the usual way, moving down to the intertransverse membrane. Below the membrane, the exiting nerve root is identified. While carefully retracting the root, the annulotomy is made at the neural foramen, and the discectomy is performed. The insertion and tethering of the PDN devices are identical to the posterior approach.
The third approach is the anterolateral transpsoatic approach (ALPA), which was first developed by Bertagnoli et al. 9, 12 Usually, the patient is placed in a right lateral decubitus position. A skin incision is made on left flank over the affected disc with the aid of fluoroscopic monitoring. The external and internal oblique muscles are retracted, the fascia of the transversalis muscle is punctured, and the retroperitoneal space is entered. Under fluoroscopic control, the correct disc space is identified, and the psoas muscle is dissected bluntly in a longitudinal direction. The psoas muscle is then retracted to expose the disc, and an annulotomy is made in a rotated H-shape. The shape of this annulotomy makes it easy to insert the PDN device and to repair the annulus. After discectomy, PDN devices are inserted using instruments specially designed for the ALPA technique. The annulotomy is closed with suture following proper positioning of the device.
RESULTS
Demographics
Forty-six of the 48 patients who underwent nucleus replacement surgery with the PDN device were followed for >6 months and were included in this study. Two patients were lost to follow-up. Of 46 patients, 30 patients were followed for >1 year and 16 for >6 months. Male and female patients were equal in number. Average age was 36.5 years (range 18-51 years). Forty patients had both chronic back pain and sciatica due to disc degeneration and concomitant disc herniation. Six patients had back pain only without sciatica. Thirty-three patients were operated at L4-L5 and 13 at L5-S1. Forty patients were operated using the posterior approach, four by the paraspinal transforaminal approach, and two by the ALPA technique. Two PDN devices were inserted in 38 patients, while one PDN device was inserted in 8 patients with smaller discs (anteroposterior disc dimension <37 mm).
Clinical Outcomes
The mean preoperative Oswestry score was 58.9%. At the 6-week follow-up visit, the mean Oswestry score was 49%, showing no significant improvement. The score did improve to 29.2% at the 3-month follow-up, 20.2% at the 6-month follow-up, and 18% at the 1-year follow-up (Fig.  1 ). The mean preoperative VAS score was 8.5. It improved to 4.5 at the 6-week follow-up and further to 3.1 at the 3-month follow-up, 3.2 at the 6-month follow-up, and 3.1 at the 1-year follow-up (Fig. 2) . The mean preoperative Prolo score was 5.2. The mean postoperative Prolo score was 5.2 at the 6-week follow-up, showing no difference from the preoperative score. It improved to 6.6 at the 3-month follow-up, 7.0 at the 6-month follow-up, and 7.2 at the 1-year follow-up (Fig. 3) .
Major surgical complications were seen in five patients (10.9%) and minor complications in two (4.4%). Four patients (8.7%) showed device extrusion that needed revision surgery, and one had an infection. Among the four patients who showed extrusion, two patients were treated by removing the extruded posterior device, while allowing the anterior device to remain in the disc. One case was revised with a larger PDN device. These three patients recovered without any residual back pain or limitation of daily activities. In one patient, the devices were removed by the anterior approach and an interbody fusion was performed. The patient who had the infection was successfully treated with an anterior interbody fusion and appropriate antibiotics. Two patients operated on with the ALPA technique had transient numbness on the left anterior thigh that resolved in 3 months.
According to MacNab's criteria, five patients (10.9%) showed excellent results, and the number of good results was 31 (67.4%). Three patients (6.5%) who showed some improvement, but their daily activities continued to be restricted due to the back pain, were classified as having fair results. Two patients had back pain worse than the preoperative state. Adding these to the five patients who had device migration and infection and thus underwent revision surgeries, seven patients (15.1%) were grouped as having poor results. Therefore, the clinical success rate according to MacNab's criteria was 78.3%.
Radiologic Findings
The mean preoperative disc height was 10.1 mm (range 7-12.6 mm). The average increase in disc height was 21.3% (range −14-55%) at the 6-week follow-up, 18.4% (range −6.9-53.1%) at the 3-month follow-up, 10.9% (range −14.7-37.3%) at the 6-month follow-up, and 9.4% (range −19.5-65.8%) at the 1-year follow-up (Figs. 4 and  5 ). Nine patients (19.6%) showed some subsidence of the devices into the endplates on plain lateral x-rays. Scleroses at the endplates, like those seen in nonunion patients in interbody fusion surgery, were seen in 28 patients (60.9%). Postoperative MRI scans were taken in 29 patients. Twenty-four of these patients (82.8%) showed aggravation of Modic changes of the vertebral body compared with those of the preoperative state (Fig. 6 ).
DISCUSSION
The three standard options for treating degenerative disc disease are conservative care, discectomy, and spinal fusion. When conservative therapy fails to improve back pain, surgery should be considered. Discectomy is primarily indicated when there is direct root compression or irritation but generally is not indicated alone for the treatment of discogenic back pain. Although removal of the nucleus pulposus can relieve nerve compression and irritation, the segment can become less stable. It has been reported that after discectomy, the disc loses its height and its ability to stabilize the vertebral column.
2,4 Fusion procedures have been successful in relieving the motioninduced discogenic pain and once were regarded as standard procedure in patients with degenerative disc disease. However, the procedure is highly invasive and eliminates segmental functional mobility; in addition, the stiffening of a motion segment induces a more rapid degeneration of an adjacent segment. 6, 7 Therefore, there is a need to seek an alternative procedure that lies somewhere between discectomy and fusion. This new technology should have properties of both restoration of disc height and maintaining the mobility of the segment.
There has been a long history of disc arthroplasty, and numerous designs of artificial discs have been developed. 8, [13] [14] [15] Total disc replacements such as the Link SB Charité and ProDisc have been in use for >10 years, and are reported to be effective in the treatment of degenerative disc disease. 16, 17 Such total disc replacement should be done by an anterior approach (a technique not familiar to the majority of spine surgeons) and may require a general surgeon or vascular surgeon to provide exposure. In contrast to total disc replacement, nucleus replacement has some advantages including the following: 1) the annulus, ligaments, and endplates are preserved; 2) the procedure is less invasive; and 3) the implant technique is more familiar to spine surgeons. There are several different designs of nucleus replacement being developed, and the future of nucleus replacement is thought to be very bright. 8, 18 As for the PDN prosthetic disc nucleus device, which is currently available in many countries, there are a few articles reporting promising clinical results. 9, 10 However, these past results were calculated from clinical data collected worldwide. Worldwide clinical data collection may have some bias and can be prone to a lack of detailed clinical information. To understand whether a device is effective in the treatment of a certain disease, clinical results with detailed information are needed.
Originally, the PDN device was developed to restore disc height and maintain segmental mobility. 10, 12 A cadaveric study showed that the PDN device restored normal range of motion and disc height in a denucleated segment. 19 In the current study, the disc height increment was maximal at 6-week follow-up, then decreased slightly and was maintained thereafter. At 1-year follow-up, the average disc height increment improvement was 9.4%, showing that the PDN device was effective in restoration of the decreased disc height caused by degeneration.
Worldwide clinical results for the PDN device for the Oswestry and VAS pain scales have shown marked improvement. 9 For 243 patients worldwide, the mean preoperative Oswestry score was 52.7. At the 6-month followup, the average score dropped to 17.4, and at the 24-month follow-up, the mean score declined to 9. For 213 patients worldwide, the preoperative VAS score was 7.1. At the 12-month follow-up, the pain score decreased to 2.49, and at the 24-month follow-up, the level of pain declined further to 1.8. The results of our current study showed a similar pattern of improvement with time but slightly less than worldwide results. The mean preoperative Oswestry score of our patients was 58.9%. After 6 months, the score improved to 20.2% and further to 18% at the 1-year follow-up. The mean preoperative VAS score was 8.5 and improved to 3.1 at the 1-year follow-up. But focusing on the 6-week follow-up data, the results were not so benign. The mean VAS and mean Oswestry scores at 6-week follow-up were 4.5% and 49%, respectively. These scores indicate that the patients were still in pain and disabilities were significant even 6 weeks after surgery. This means that the clinical recovery was very slow. Bertagnoli et al 9 reported that some patients showed temporary postoperative increase in low back pain and that the pain was minor and lasted a relatively short period of time. But our current study showed that many of the patients suffered from significant back pain postoperatively, which lasted for at least 6 weeks. Even though the clinical symptoms showed improvement after Ն3 months, significant back pain during the first 1 or 2 months of the postoperative period can be a problem to both the physician and the patient. The cause of the early postoperative pain is yet to be determined. Bertagnoli et al 9 proposed that the pain represents a reaction to segmental distraction caused by the hydrating implants. They also noted moderate to severe endplate changes in some patients implanted with the PDN device and postulated that this endplate remodeling was due to the changes of load distribution. Their observation is supported by subsidence of devices in nine patients and sclerosis of endplates seen in 68.9% of the patients in our study. In this current study, 82.8% of the patients with postoperative MRI showed aggravation of Modic changes of the vertebral body. It is unclear if these Modic changes were solely caused by a mechanical reason like load redistribution or caused also by an inflammatory reaction. Moreover, the clinical implication of these changes is not yet known.
Extrusion and migration seem to be the main obstacles that keep nucleus replacement devices from being widely accepted and used. 8, 18 The PDN device also has had a history of extrusions, and there have been modifications of the surgical technique and design of the device to overcome the problem. 10 The extrusion rate of our current series was 8.7%, not much different from that of the worldwide results (12%). There are recommended guidelines in patient selection to prevent extrusion.
9,12 These guidelines include not inserting the PDN device in obese patients or patients with an incompetent annulus and not inserting two PDN devices in patients with an anteroposterior disc diameter of <37 mm. However, we believe that extrusion of the devices is closely related to surgical technique as well as to patient selection. The four patients who showed extrusion were operated on during the initial stage of our learning period-fewer than 10 cases of experience. The possible causes of extrusion in our series were tethering failure, insufficient preparation of the disc space, and choosing a PDN size that was too small for the patient. In one patient, the tethering suture that holds both devices together was cut off during insertion of the posterior device but was left without correction because the position of devices seemed to be perfect. At 6 weeks after surgery, the patient developed sudden sciatic pain, and it was found that the untethered posterior device extruded. At the time of revision surgery, it was found that the devices were too small and easily movable in the disc space. The devices were removed and replaced with larger ones. Another three cases of device extrusion showed rotation of devices on intraoperative x-rays or postoperative x-rays taken immediately after ambulation. In one patient, intraoperative x-rays showed improper transverse direction of the PDN device, but surgery was ended because all efforts to correct the position of the device failed. Several days after the surgery, the patient developed leg pain because of the extrusion, and revision surgery was done by anterior interbody fusion. It was postulated that inadequate preparation of the disc space in the transverse dimension interfered with proper positioning of the PDN device in this case. The other two patients showed perfect positioning of the device on intraoperative x-rays, but x-rays taken immediately after ambulation showed some rotation of the devices. Recoveries were uneventful and their clinical outcomes were excellent, but both of them developed leg pain at 6 months after surgery, and it was found that the rotated device extruded posteriorly. In our opinion, rotation of the devices implies poor preparation of the disc space (ie, insufficient removal of nucleus material), especially in the transverse dimension of the disc. Disc preparation in the transverse dimension should be at least 25 mm to make enough room for the PDN device to lie in a transverse direction. If preparation of the disc is not adequate, the remaining nucleus material can exert force on the PDN device, causing it to rotate and extrude later. In all the patients with an extrusion, inadequate preparation of the disc space was confirmed with retrospective review of postoperative CT scans. There are three different sizes of PDN devices, designed to correspond with the patient's disc height, and an appropriately sized PDN device should be chosen using the device-sizing instrument. If too small a PDN device is chosen for ease of introduction into the disc space, it does not fill the whole height of the disc and can move and extrude later. We believe that the combination of these possible causes made the PDN devices extrude in our series. After we assumed the possible causes of extrusion, we modified our surgical technique in the posterior approach and adopted the paraspinal transforaminal approach and the ALPA technique. Since we have changed our surgical tactics, no other extrusion has occurred. Recently, the tethering suture material was changed to a polyester band, and the tethering technique was modified. A new PDN design called the PDN-SOLO is now used in patients with small anteroposterior disc dimension. We expect that all these changes can reduce the extrusion rate further.
The articles reporting worldwide clinical results describe a surgical success as 88-90%. 9, 10 However, this success rate is based only on successful implantations (ie, cases without revision surgery). It is important to remember that not all the patients can be classified as a clinical success just because implantation was successful. Surgical success should be differentiated from clinical success. To evaluate the efficacy of any medical device, it is important to know what proportion of the patients with successful implantation also enjoyed clinical success. That is why this study used another clinical outcome scale, MacNab's criteria. 11 In this study, three cases were grouped as fair and two as poor, in spite of successful implantation of the PDN device thus the clinical success rate among the patients with successful implantation was 87.8%. We expect that the overall success rate will improve as the extrusion rate decreases by some changes in tethering material and implant methods as well as by recent changes in the design of the device. Indications and contraindications are described as crucial variables in predicting surgical success for the PDN device. 9 Currently, the indications are restricted to degenerative disc disease manifested by back pain with or without leg pain. 10 The guidelines were followed in this study, but the majority of the patients were those who had back pain with leg pain because we were reluctant to do discectomy and nucleus replacement by a posterior approach in a patient who had no leg pain. The PDN device has been developed as an alternative to spinal fusion for patients with degenerative disc disease and back pain. Our early results suggest that nuclear replacement with the PDN device is an effective treatment modality in patients with moderate to severe degenerative disc disease (regardless of sciatica) who otherwise would have been treated with fusion surgery.
CONCLUSION
The PDN device was effective in patients with degenerative disc disease who had chronic back pain with or without leg pain. But clinical improvement was very slow, and early postoperative pain was significant (the cause of this pain is still unclear). Device extrusion was also a problem, but it seems that it will be overcome in the near future by improvement in device design and refinement of the surgical techniques. What we learned from our experience is that to minimize the device extrusion problem, surgeons should receive detailed training on the operative techniques and patient selection before performing their first surgery.
Nucleus replacement with the PDN device has merit because it can treat both back pain and leg pain in a much less invasive way than fusion surgery. But long-term data are still necessary to determine the efficacy of the PDN device in treating degenerative disc disease without negative influence on the adjacent motion segments. Longterm data about the reaction of vertebral endplates to the devices need to be collected and analyzed to understand better the clinical implications of endplate remodeling and Modic changes on the vertebral bodies.
